Phase 1/2Data readout

INKmune™

Cancer, Prostate cancer, Castration-resistant prostate cancer

INMBINmune Bio

Expected catalystDecember 31, 2026Company guidance: Dec 31, 2026

Catalyst overview

Event details

Drug or asset: INKmune™
Development stage: Phase 1/2
Event type: Data readout
Indication: Cancer, Prostate cancer, Castration-resistant prostate cancer

Research summary

What is being tracked?

This catalyst tracks a Phase 1/2 data readout for INKmune™ in Cancer, Prostate cancer, Castration-resistant prostate cancer. The expected timing is based on the latest available company guidance and may change.

Development notes

CaRe PC. 1/28/25- First patient treated. Expands trial to veterans. 2/12/25- Completed third & highest dose cohort. 8/4/25- Met primary & secondary endpoints. To proceed to Ph2b. 10/30/25:- Enrollment closed; follow-up completes in Q4 2025; final data in Q4 2026. 05/07/26:- PR No update. 08/06/26:- PR No update.

Verification

Primary source

Confirm timing and program details against the company announcement or filing.

Source URL not provided